Drug
SF 1126 clinical trials
Also written SF1126.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
- SF1126
- 4
Studies by the year they started
4 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 2
Semafore Pharmaceuticals (1) · SignalRX Pharmaceuticals, Inc. (1) · New Approaches to Neuroblastoma Therapy Consortium (1) · Ezra Cohen (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses SF 1126 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular CarcinomaTerminatedPhase 1SignalRX Pharmaceuticals, Inc.NCT03059147Written as SF1126
- SF1126 for Patients With Relapsed or Refractory NeuroblastomaTerminatedPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT02337309Written as SF1126
- SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway GenesTerminatedPhase 2Ezra CohenNCT02644122Written as SF1126
- A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid TumorsCompletedPhase 1Semafore PharmaceuticalsNCT00907205Written as SF1126
Codes
What other systems call SF 1126 · ClinicalTrials.gg INT005228
- UNII (FDA) DL0Q912033SF-1126Confirmed FDA, Wikidata
- Wikidata Q27276459sf-1126Confirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DL0Q912033 | SF-1126 | Confirmed FDA, Wikidata |
| Wikidata | Q27276459 | sf-1126 | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.